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Hepatic Retransplantation 
B.W. Shaw, Jr, R.D. Gordon, S. Iwatsuki, and T.E. Starzl 
DESPITE RECENT improvements in 
operative techniques,I.2 immunosup-
pression,I.3.4 and organ procurement,5-7 failure 
of a hepatic allograft remains an important 
risk to liver recipients. In the absence of any 
effective method of extracorporeal support, 
the only alternativ(1to death for these patients 
is retransplantation (RETX). The need for 
RETX can occur in one of three settings: 
emergent, acute, and elective. Proper timing 
of elective RETX requires balancing the risk 
of further attempts to rescue the primary 
graft against the risks of reoperation. Success-
ful use of RETX in the emergent and acute 
settings requires an effective organ procure-
ment system and optimization of all availabie 
donors. 
The present study involves a review of the 
experience obtained from the sequential 
transplantation of two or more hepatic grafts 
into 70 patients over a 21-year period. 
MATERIALS AND METHODS 
Data Analysis 
From March I, 1963, to Feb 3, 1980, of the 170 liver 
recipients transplanted at the University of Colorado 
under conventional immunosuppression with azathioprine 
and prednisone (AZA-P), 21 required RETX. Survival 
data are provided for this group to allow a comparison 
with similar data obtained from 199 patients treated at 
Colorado (14 patients) and at the University of Pitts-
burgh Health Center (185 patients) with cyclosporine 
and prednisone (CYCLO-P), among whom 49 required 
RETX. 
The major causes for RETX were reviewed and desig-
From the Department of Surgery, University of Pitts-
burgh Health Center. 
Supported by research grants from the Veterans 
Administration and project grant No. AM-29961 from 
the National Institutes of Health, Bethesda, Md. 
Address reprint requests to Byers W. Shaw, Jr, MD, 
Department of Surgery, 3601 Fifth Ave, Room 103, Falk 
Clinic, Pittsburgh, PA 15213. 
© 1985 by Grune & Stratton, Inc. 
0041-1345/85/1 701---{)091 $03.00/0 
264 
nated as either primary nonfunction of a graft (PNF), 
rejection, or technical causes (TECs). 
A diagnosis of PNF was made if a graft never demon-
strated evidence of initial function following transplanta-
tion. Such evidence would include not only frank signs of 
total hepatic failure (eg, profound hypoglycemia, uncor-
rectable coagulopathy, stage IV coma, renal failure, 
acidosis, and cardiodynamic shock), but also other signs 
of irreparable damage to the organ (ie, massive rises in 
transaminases along with unrelenting daily rises in biliru-
bin, persistent renal insufficiency, mental confusion and 
persistent coagulopathy). 
Any secondary failure of a graft, following an initial 
period of acceptable function, was assigned to one of the 
other two categories. Rejection was diagnosed mainly on 
clinical grounds. The histopathology of the grafts 
removed was reviewed as well. A TEC classification was 
assigned to all grafts failing from vascular thromboses, 
complications of biliary tract reconstruction, or other 
errors in operative technique. 
Survival data are calculated using life table methods. 
All CYCLO-P patients have been observed for at least six 
months. All AZA-P patients have died. 
Blood usage data were collected for all patients trans-
planted from Jan I, 1983, to Aug I, 1984. Paired t tests 
were used to compare the means of operative blood loss 
during the first transplant to those during the second. 
Median data was compared using a rank sum test. 
The presence of cytotoxic T-warm antibodies in both 
groups of patients undergoing one liver transplant, and 
those requiring more than one, was examined using 
methods previously described l and compared using chi-
square analysis. 
RESULTS 
Incidence of Retransplantation 
RETX under AZA-P therapy was used 
infrequently, with only 21 of 170 patients 
(12.4%) during a 19-year period receiving 
second hepatic grafts. The increasing impor-
tance of RETX since the introduction of 
cyclosporine as an immunosuppressant is 
illustrated graphically in Fig 1. Over a five-
year period ending Aug 1, 1984, 69 of 323 
total operations (21.4%) have been RETX's. 
Of these 69 reoperations, 60 were second 
transplants and nine were third transplants. 
No RETXs occurred in 1980, although one 
patient receiving a first graft in that year 
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Fig 1. liver transplants per calendar year. 18l. 
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received retransplants twice in 1982. During 
1983, the retransplant rate increased to 
26.9%, the highest in any year thus far. 
The primary disease categories and the 
proportion of patients receiving RETX for 
each are shown in Fig 2. No significant differ-
ence in incidence of RETX was found among 
the disease categories, except that none of the 
12 primary hepatic tumor patients required 
RETX. Furthermore, Fig 3 shows that the 
causes of RETX occurred at a frequency that 
was not significantly different among the dis-
ease entities, except that technical failures did 
not occur in the primary biliary cirrhosis or 
sclerosing cholangitis groups. 
Of the three major causes of hepatic graft 
loss, rejection was by far the most common, 
occurring in 28 of the 49 patients-IS of 24 
adult patients and 13 of 25 pediatric patients 
NUMBER OF GRAFTS 
Fig 2. liver retransplantation with cyclosporine 
and prednisone: primary disease categories. ~K 
Retransplants; _. first grafts. 
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Fig 3. Indications for liver retranplantation: cyclos-
porine era. 121. Primary nonfunction. n ~ 11; 18l. technical 
failure. n ~ 10; _. rejection. n ~ 28. 
(Fig 4). TECs occurred with greater fre-
quency in children than in adults (P < .05). 
Timing of Retransplantation 
The interval between the first and second 
transplant operations compared with both the 
causes for RETX and subsequent survival for 
six months or more is illustated in Fig 5. TEC 
failures and those secondary to PNF required 
early rather than late reoperation, whereas 
rejection appeared to occur throughout the 
time course, with a noticeable cluster of 
patients at the one-week and the 60-day inter-
vals. Seven patients received retransplants 
more than 90 days after primary grafting. 
Two subsequently died of sepsis related to 
overimmunosuppression, and two others died 
of technical failures. Three of these patients 
have survived, two for more than two years 
and one for 13 months. 
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Fig 4. Indications for retransplantation. 
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Fig 5. Timing of retrans-
plantation. •• Alive at >6 
months; X. dead before six 
months. 
Major Causes of Death 
Figure 6 plots the causes of death against 
the primary cause for RETX. The chart 
emphasizes the dominant role that sepsis with 
mUltiple-organ failure played in the death of 
these patients. This is particularly evident 
when examining patients receiving retrans-
plants for chronic rejection or in whom the 
first grafts failed to provide adequate func-
tion. The technical causes of death include one 
patient with both portal vein and arterial 
thrombosis in the second graft and two 
patients with ruptured mycotic aneurysms of 
the donor hepatic arterial supply. Three 
patients died of irreparable brain injury fol-
lowing RETX. All three were returned to the 
operating room in deep coma secondary to 
profound hepatic allograft failure, two within 
seven days of primary grafting and one after 
16 days. Three patients died of predominant 
hepatic failure. 
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Survival Data 
Patients under CYCLO-P therapy had a 
markedly better one-year survival rate than 
those under AZA-P (49% v 14%; P < .001) 
(Fig 7). A breakdown of overall survival of all 
patients, comparing survival of primary v sec-
ondary grafting and adults v children is shown 
in Fig 8. All patients who required only pri-
mary grafting fared better at one year than 
those who required RETX, with 68.5% of the 
former and 49% of the latter surviving at least 
one year (P = .014). This relationship holds 
true when primary and secondary grafting are 
compared in adults (63.5% v 42.3%; P = .026) 
and children (76.8% v 56.5%; P = .042) at one 
year. Children obtained better one-year 
survival than adults in the primary group 
(P = .038); but not in the retransplant group 
(P = .159). 
A further breakdown of the survival for 
retransplanted patients based upon primary 
disease ca tegories is shown in Fig 9. All curves 
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Fig 7. Actuarial survival after liver retransplanta-
tion. before and after the introduction of cyclosporine-
Fig 6. Majorcauseofdeathvcauseforretransplan- prednisone therapy. -*-. CYCLO-P. n = 49; --0--. 
tation. AZA-P. n = 21. 
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Fig 8. Actuarial survival after liver retransplanta-
tion with cyclosporine and prednisone in pediatric and 
adult patients. -*-. One graft. pediatric; --0--. one 
graft. adult; .. 0 . '. retransplanted. pediatric; --/::;.--. 
retransplanted. adult. 
are virtually flat after six months, since no 
deaths have occurred later than six months in 
any retransplant group. Survival at six months 
and beyond for each group is not significantly 
different from the overall survival for the 
entire population of retransplanted patients. 
Patients with biliary atresia had the best 
overall survival, and those with sclerosing 
cholangitis the worst, following RETX, but 
these differences are not significant (P = 
.074). 
Figure 10 illustrates the survival of patients 
dependent upon the cause of RETX. Both 
rejection and TEC patients had better survival 
after six months than PNF patients (P ~ .029 
for rejection v PNF; P = .015 for TECs v 
PNF). 
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Fig 9. Actuarial survival after liver retransplanta-
tion with cyclosporine and prednisone: primary diagnos-
tic categories. -*-. Biliary atresia: --0--. primary 
biliary cirrhosis; ·.0··. inborn errors of metabolism; 
--/::;.--. all patients; -. * .-; cirrhosis; -·0·-. scle-
rosing cholangitis. 
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Fig 10. Actuarial survival for liver transplantation. 
based on indications for graft replacement. -*-. 
Rejection. n ~ 28; --0--. technical failure. n - 10; 
. . 0 . '. primary nonfunction. n ~ 11. 
Finally, the overall effect of RETX on 
survival is demonstrated in Fig 11. The lower 
curve assumes that all RETX patients not 
retransplanted would have died on the date of 
RETX. As a comparison, one can look at the 
causes of death among seven patients for 
whom appropriate donors could not be located 
in time (Table 1). The technical PNF, and 
acute rejection causes of graft failure created 
emergent situations in which the availability 
of appropriate donors could have been life-
saving. The two cases of death following 
chronic rejections occurred in patients in 
whom the over-use of immunosuppression led 
to eventual sepsis, subsequent multiple-organ 
failure, and death. Both were pediatric recip-
ients in whom the decision to retransplant was 
made early, but for whom appropriate donors 
were not made available before sepsis 
developed. 
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Table 1. Seven Patients for Whom Donors 
Were Not Available in Time 
Cause of 
Graft Failure 
Cause of 
Death 
Technical 
Technical 
Hepatic gangrene 
Primary nonfunction 
Acute rejection 
Acute rejection 
Chronic rejection 
Chronic rejection 
Blood Usage 
Hemorrhage 
Hepatic failure 
Hepatic failure 
Hepatic failure 
Sepsis 
Sepsis 
As seen in Table 2, the mean operative 
blood loss in patients undergoing primary 
grafting is significantly greater than in those 
with RETX. This is true in both adults and 
children, although in the latter group, in order 
to see a difference, one must eliminate from 
consideration the three cases of arterial 
thrombosis (see Discussion). These data were 
obtained only for 1983 and 1984, since venous 
bypass was introduced in all adult patients 
beginning in early 1983. The use of venous 
bypass has resulted in a significant reduction 
in operative blood use.2 
Crossmatch 
Information regarding the presence or 
absence of donor-specific cytotoxic T cell anti-
bodies in the serum of liver recipients was 
available in 148 patients but was not available 
in another 92 (Table 3). 
RETX did not occur with a greater fre-
quency in those patients with a positive cross-
Table 2. Operative Blood Use: First Versus Second 
Hepatic Transplantation 1983 to 1984 
First Graft Second Graft PValue 
Adults (n - 20) 
Mean 37.9 ± 37.2 16.5 ± 12.9 <.05 
Median 29 16 <.02 
Range 4-157 1-56 
Children (n - 16) 
Mean 10.9 ± 7.0 5.5 ± 2.5 <.05 
(9.7 ± 10.6)· 
Median 10 5 <.01 
Range 3-25 2-11 (2-36)* 
Values expressed are units of packed RBCs. 
*If cases of arterial thrombosis are included (see Discus-
sion). 
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Table 3. Hepatic Retransplantation: Influence of 
Donor-Specific Cytotoxic T Cell Antibodies 
Negative Positive Not 
Crossmatch Crossmatch Done 
No retransplant 94 21 76 
All retransplants 27 6 16 
Rejected retransplants 16 4 8 
match than in those with a negative cross-
match. 
Similarly, the incidence of a positive cross-
match was no greater among the RETX popu-
lation than it was among those requiring only 
one graft. More importantly, the frequency of 
a positive cross match was no greater in 
patients given RETX for rejection than it was 
in PNF or TEes. 
As reported previously, the incidence of a 
positive cross match at the time of the first 
transplant increased from approximately 25% 
to 50% at the time of RETX and to 75% at the 
time of tertiary RETX.8 
Tertiary Transplants 
A subgroup of nine patients has been given 
three sequential hepatic allografts (Table 4). 
Four are dead. One developed chronic rejec-
tion and required a second graft 572 days 
after primary grafting. The second graft 
failed to function, and a third transplant was 
performed seven days later. Death occurred 
14 days later in the face of candida septicemia 
and irreversible brain injury. The second 
patient had severe arteriovenous shunting sec-
ondary to chronic liver disease. The first liver 
failed due to PNF and was replaced four days 
later. The second graft eventually failed 
because of persistent severe hypoxia in the 
recipient, as did a third, transplanted 57 days 
Table 4. Tertiary Hepatic Transplantation 
as of Aug 1. 1984 
Dead Alive 
Interval from 7,10, 19, 13,28,41, 
2nd to 3rd 57 d 120,264 d 
transplant 
Survival 9,10,14, 7, 9, 11, 17. 
after 3rd 43 d lamo 
transplant 
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later. Massive intracranial hemorrhage led to 
the patient's death 46 days following the final 
transplant. Two other patients received third 
grafts when their second livers were lost to a 
form of relentless rejection similar to that 
which destroyed their first grafts. In both 
cases, death occured ten days after tertiary 
grafting, predominantly the result of liver 
failure and sepsis. Both of these latter patients 
were in stage III or IV hepatic coma with 
renal failure requiring dialysis, cardiody-
namic instability, and severe coagulopathy at 
the time of the third transplantation. 
Five patients are alive after tertiary liver 
transplantations. They have survived for 7, 9, 
11, 17, and 18 months. Three are male chil-
dren between the ages of 2 and 4 years. All 
three are at home and doing well. The two 
adults include a 26-year-old man and a 45-
year-old woman, both of whom remain well 
and quite active. 
DISCUSSION 
Modifications of Recipient and Donor 
Procedures 
A few minor changes in technique useful 
when performing an hepatic RETX are worth 
noting. 
The utility of procuring vascular grafts in 
concert with the donor liver has been empha-
sized before.9 This precaution is even more 
important in the setting of RETX, particu-
larly if a vascular thrombosis is the cause of 
graft failure, since an alternative method of 
arterial or portal venous reconstruction may 
be required. 10.1 I 
The recipient operation may vary signifi-
cantly, depending upon the time interval since 
the first transplant operation. Early reopera-
tions, as one might expect, require very little 
dissection to allow for removal of the graft. On 
the other hand, if other than thin filmy adhe-
sions are encountered, care must betaken to 
avoid overly aggressive blunt dissection, since 
the vessel walls of the donor organ may prove 
to be the weakest point in the area being 
stressed. Sharp dissection along tissue planes, 
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along with judicious use of electrocautery, 
may minimize blood loss. 
In three cases of hepatic artery thrombosis 
in children, collateral arterialization of the 
graft through adhesions of the liver to the 
daiphragm, bowel, and omentum occurred. In 
all three, blood loss the second time exceeded 
that during the first transplant by a factor of 
three or more (Table 2). 
When removing the failed hepatic graft, the 
upper vena caval anastomosis is left intact, 
and a short cuff of vein from the liver being 
removed is left in place to allow enough length 
for anastomosis with the new organ (Fig 12). 
Portions of the first liver's lower vena cava and 
portal vein may also be reused if extra length 
is needed. Portions of graft hepatic artery, on 
the other hand, are never reused, since in three 
cases, necrosis in the vessel wall associated 
with a mononuclear infiltrate in the media of 
the artery has resulted in arterial thrombosis 
or rupture. 
Biliary reconstruction in RETX requires 
careful assessment of the viability of the recip-
ient duct tissue and removal of all duct tissue 
from the first donor if a duct-to-duct anasto-
mosis is to be redone. Construction of a Roux-
en-Y jejunal loop may be necessary if the 
recipient bile duct is of inadequate length or 
insufficient quality. Reuse of a jejunal loop 
requires closure of the first anastomostic site 
Donor liver 
Fig 12. Intact upper vena caval anastomosis with 
short cuff of vein from the liver being removed, which is 
left in place for anastomosis with the new organ. 
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and choledochoenterostomy at another point 
along the limb. 
Clinical Setting of Retransplantation 
Massive hepatic necrosis secondary to 
rejection or hepatic gangrene from arterial 
thrombosis occurs infrequently but requires 
emergency RETX. Although only three of the 
49 patients in this series fall into this category, 
three others did die before a donor could be 
found. Early RETX is also required for PNF, 
but seldom on an emergent basis. Acute and 
chronic rejection caused graft failure predom-
inantly at two intervals: seven to ten days and 
six to eight weeks. In the former cases, the 
decision to retransplant was seldom difficult 
in the face of liver failure unresponsive to all 
therapy. The latter cases occurred on a more 
elective basis, although urgency was present 
on those occasions where marked clinical 
deterioration began to occur before donors 
became available. 
Developing clinical criteria that accurately 
determined a need for RETX in the elective 
setting is impractical with only 49 patients. 
However, some useful general guidelines can 
be set forth. These guidelines are based on the 
observation in the present series: (l) that 
survival after RETX approaches that of pri-
mary grafting; (2) the major cause of failure 
after RETX is sepsis; (3) the RETX operation 
is generally less difficult than primary graft-
ing, for both the surgeon and the recipient; 
and (4) failure of a second transplant does not 
preclude survival after a third, since five of 
nine such patients are alive and well. 
In the first month after grafting, all 
patients with a persistent elevation of bilirubin 
above 10 mg/dL (with or without elevation of 
transaminase), which is unresponsive to two 
full courses of antirejection therapy, I and 
those without evidence of correctable lesions 
should be considered for RETX. The same 
holtis for any patient, regardless of serum 
bilirubin levels, whose liver function deterio-
rates rapidly when steroid doses are reduced 
to acceptable maintenance levels (approxi-
mately 20 to 30 mg daily in adults and 10 to 
20 mg daily in children), or who is receiving 
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frequent intravenous bolus injections of ste-
roids in an attempt to control rising liver 
function tests. Liver biopsy may help to con-
firm the diagnosis of rejection, but absence of 
classical signs does not rule out rejection. The 
presence of viral inclusion particles may allow 
appropriate antiviral therapy to be instituted, 
but this rarely results in significant long-term 
improvement since rejection is almost always 
a predominant accompanying feature. 
Patients who develop rejection after several 
months of normal liver function seldom 
respond to manipulations of immunosuppres-
sion. A biopsy that shows signs of chronic 
rejection (arteriolar thickening, extensive 
periportal fibrosis, and disappearance of bile 
ductules) indicates irreversible destruction in 
most cases. The presence of massive elevations 
of serum cannilicular enzymes, particularly 
gamma glutamyl transpeptidase levels, is an 
ominous sign as well. Vigorous rescue efforts 
with increasing immunosuppression in this 
setting should be abandoned in favor of elec-
tive RETX. 
In all cases, thorough and repeated efforts 
should be made to exclude the possibility of 
correctable lesions, such as drug toxicity, bil-
iary leaks, obstruction, or intra abdominal 
abscess. Angiography in the face of overt graft 
failure is an unnecessary risk since RETX will 
be necessary anyway, but it may allow an 
earlier decision to be made for RETX in less 
obvious situations. 
SUMMARY 
RETX resulted in significant improve-
ments in survival in a large series of liver 
transplant patients. One-year survival follow-
ing RETX is not as good as following primary 
transplants, but the rate approaches 50% for 
all patients, 60% for children, and 45% for 
adults. RETX occurs in a variety of clinical 
settings but results from one of three major 
causes: rejection, PNF, or TEes. The need for 
RETX can be emergent, acute, or elective. 
The decision for RETX is usually obvious in 
the emergent and acute settings. Guidelines 
for making the decision in the elective situa-
tion have been outlined. 
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